Ukraine war expected to have long-lasting impact on clinical development
Many clinical trials have been put on hold or cancelled due to the war in Ukraine
The war in Ukraine has caused the delay and cancellation of “pivotal” clinical trials and will likely have long-lasting, global effects on clinical development, according to a new report by clinical tech services company Phesi.
The report focused on “pivotal” trials sponsored by pharmaceutical companies that represent the most critical global clinical development activities. As of March 16, 2022, there were 65,593 recruiting investigator sites globally in this category.
Of these, 2,911 (4.4%) sites were based in Ukraine and Russia, with most pharmaceutical trials currently in Phase III. Investigator sites in these countries are now on hold or have been cancelled, due to the ongoing conflict, related supply issues and financial sanctions. A further 1,738 (2.6%) sites in neighbouring Poland are also now at elevated risk.
The disruption to investigator sites will impact some research areas more than others. For example, more than 25% of all trials in schizophrenia take place in Ukraine and Russia, as well as a high proportion of gastrointestinal disease studies - including ulcerative colitis (14%) and Crohn’s disease (10%).
Sponsors will also experience varying degrees of disruption, with companies employing a global development strategy likely getting hit hardest. Companies with a large presence in the region include Eli Lilly (8% of their sites in Ukraine and Russia) and Merck (7%).
Phesi CEO Gen Li says redistributing investigator sites will be “painful, costly, and chaotic” for impacted companies.
“Whilst the war is happening in a single country, the impact for the clinical development industry will be global and long-lasting. Coming on top of the pandemic and with many countries still implementing lockdowns, it’s an increasingly difficult time for pharmaceutical companies,” he said.
In addition to the impact on local sites, there will also likely be a drop-off in terms of wider patient availability.
Phesi Chief Medical Officer Paul Chew notes that Ukraine, Russia and Poland contribute “significantly more patients on average, which exacerbates the impact beyond the number of sites in just these countries.”
He said: “Whilst the region will not see many trials returning in the short-term, we urge sponsors to retain their links with investigators and academics based there and keep the lines of communication open. They should also continue to fund sites, even those that are suspended.”
The report recommends that companies utilise data, including synthetic data, to get trials over the line. In some cases there may already be enough data available to close knowledge gaps and get treatments out to patients. It also encourages companies to consider conducting studies remotely and virtually.
In our role connecting international communities, CPHI/Pharmapack knows first-hand that progress and problem-solving comes from working together, not against one another. We stand firmly with the people of Ukraine, most notably our customers and partners, and their loved ones in the region, and with all who are championing harmony, unity and progress toward peace.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance